Shopping Cart
- Remove All
- Your shopping cart is currently empty
RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist (human RORγt-LBD) with an IC50 of 19 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 6-8 weeks | |
50 mg | $2,180 | 6-8 weeks | |
100 mg | $2,800 | 6-8 weeks |
Description | RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist (human RORγt-LBD) with an IC50 of 19 nM. |
Targets&IC50 | RORγt:19 nM |
In vitro | RORγt Inverse agonist 8 is a potent inhibitor of RORγt and binds to the ligand binding domain (LBD) of RORγt. RORγt Inverse agonist 8 results in complete attenuation of IL-17A secretion in a concentration-dependent manner (IC50 of 60 nM in HUT78 cells). RORγt Inverse agonist 8 selectively suppresses human Th17 and Tc17 cell differentiation. RORγt Inverse agonist 8 reduces Th17 cell-associated mRNA expression including IL17A, IL17F, IL26, IL23R and CCR6 in a concentration-dependent fashion. |
In vivo | antigen-induced arthritis (AiA) responses in Lewis rats ameliorated by RORγt Inverse agonist 8. |
Molecular Weight | 475.59 |
Formula | C26H33N7O2 |
Cas No. | 2079892-79-6 |
Relative Density. | 1.35 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.